← Back to Search

Testing Strategies for Safe School Return During COVID-19

N/A

Waitlist Available

Led By Jason G. Newland, MD

Research Sponsored by Washington University School of Medicine

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to one year

Awards & highlights

Study Summary

This trial will help to understand the best way to test for SARS-CoV-2 in order to safely return to in-person schooling.

Who is the study for?

This trial is for students and staff in five specific school districts, as well as their household members. It aims to find the best COVID-19 testing strategy for safe return to in-person schooling in underserved areas of St. Louis.Check my eligibility

What is being tested?

The study compares two SARS-CoV-2 testing strategies: one where only people with symptoms are tested (symptomatic testing), and another that adds regular weekly tests regardless of symptoms (weekly surveillance). The goal is to see which method better prevents virus spread at schools.See study design

What are the potential side effects?

Since this trial involves non-invasive COVID-19 testing strategies rather than medication or vaccines, there are no direct medical side effects. However, participants may experience discomfort from nasal swabs or anxiety related to test results.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to one year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to one year

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to one year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

School based transmission

Trial Design

2Treatment groups

Active Control

Group I: Weekly Screening testing plus symptomatic testingActive Control1 Intervention

Among 16 middle and high schools, 8 will be randomized to offer students and staff weekly SARS-CoV-2 testing. Additionally, these schools will offer testing for symptomatic students, staff, household members in all age groups.

Group II: Symptomatic testingActive Control1 Intervention

All 16 schools will have testing available for individuals that have symptoms or need a test for other reasons.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Washington University School of MedicineLead Sponsor

1,931 Previous Clinical Trials

2,297,235 Total Patients Enrolled

Jason G. Newland, MDPrincipal InvestigatorWashington University School of Medicine

2 Previous Clinical Trials

4,600 Total Patients Enrolled

Media Library

Weekly Screening testing plus symptomatic testing Clinical Trial Eligibility Overview. Trial Name: NCT04875520 — N/A

Coronavirus Research Study Groups: Weekly Screening testing plus symptomatic testing, Symptomatic testing

Coronavirus Clinical Trial 2023: Weekly Screening testing plus symptomatic testing Highlights & Side Effects. Trial Name: NCT04875520 — N/A

Weekly Screening testing plus symptomatic testing 2023 Treatment Timeline for Medical Study. Trial Name: NCT04875520 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there vacancies available for this clinical trial?

"The clinical trial's information on the clinicialtrials.gov website indicates that no participants are being sought at present. The study was opened on May 7th 2021 and most recently updated August 22nd 2022, yet there are an abundance of other trials actively recruiting now with 1,040 studies available for potential candidates to join."

Answered by AI

In what localities is this experiment conducted?

"Five locations are hosting this trial, including The School District of University City in University City, Pattonville School District in Saint Ann, and Jennings School District in Jennings. Additionally there are two further sites taking part."

Answered by AI

Recent research and studies

The Lancet Infectious DiseasesJournal

Temporal Profiles of Viral Load in Posterior Oropharyngeal Saliva Samples and Serum Antibody Responses During Infection by Sars-cov-2: An Observational Cohort Study

To, Kelvin Kai-Wang, Owen Tak-Yin Tsang, Wai-Shing Leung, Anthony Raymond Tam, Tak-Chiu Wu, David Christopher Lung, Cyril Chik-Yan Yip, et al.. 2020. “Temporal Profiles of Viral Load in Posterior Oropharyngeal Saliva Samples and Serum Antibody Responses During Infection by Sars-cov-2: An Observational Cohort Study”. The Lancet Infectious Diseases. Elsevier BV. doi:10.1016/s1473-3099(20)30196-1.

MMWR. Morbidity and Mortality Weekly ReportJournal

Racial and Ethnic Disparities in COVID-19 Incidence by Age, Sex, and Period Among Persons Aged <25 Years — 16 U.S. Jurisdictions, January 1–december 31, 2020

Van Dyke, Miriam E., Maria C.B. Mendoza, Wen Li, Erin M. Parker, Brook Belay, Elizabeth M. Davis, Joshua J. Quint, Ana Penman-Aguilar, and Kristie E.N. Clarke. 2021. “Racial and Ethnic Disparities in COVID-19 Incidence by Age, Sex, and Period Among Persons Aged MMWR. Morbidity and Mortality Weekly Report. Centers for Disease Control MMWR Office. doi:10.15585/mmwr.mm7011e1.

Child Development PerspectivesJournal

Child Development During the COVID‐19 Pandemic Through a Life Course Theory Lens

Benner, Aprile D., and Rashmita S. Mistry. 2020. “Child Development During the COVID‐19 Pandemic Through a Life Course Theory Lens”. Child Development Perspectives. Wiley. doi:10.1111/cdep.12387.

PediatricsJournal